Isomorphic Labs, the artificial intelligence drug discovery company spun out of Google DeepMind, has raised $2.1 billion in a Series B round led by Thrive Capital, bringing total external funding to approximately $2.6 billion and establishing the company as one of the most heavily capitalised private biotech ventures in the world.
The round included participation from Alphabet, its venture arm GV and growth fund CapitalG, alongside new sovereign wealth investors including Abu Dhabi's MGX, Singapore's Temasek and the UK Sovereign AI Fund. The geographic and institutional diversity of the investor base is deliberate: Isomorphic is positioning itself not merely as a Silicon Valley AI startup but as a globally significant pharmaceutical infrastructure company with backing from some of the largest pools of patient capital on Earth.
The company was founded in 2021 by Sir Demis Hassabis, who serves as chief executive of both Isomorphic and Google DeepMind, and who won the 2024 Nobel Prize in Chemistry for AlphaFold, the AI system that solved the decades-old problem of predicting protein structures from amino acid sequences. AlphaFold's database of predicted structures for virtually every known protein has been used by more than two million researchers worldwide and is widely regarded as one of the most consequential scientific breakthroughs of the past quarter century.
Isomorphic's thesis is that AlphaFold was the beginning, not the end, of what AI can do for drug discovery. The company has built an AI Drug Design Engine called IsoDDE that extends beyond structure prediction into the full pipeline of drug development: identifying disease targets, designing molecules that interact with those targets, predicting how those molecules will behave in the body, and optimising them for safety, efficacy and manufacturability.
The promise is transformative. Traditional drug development takes an average of 10 to 15 years from discovery to approval, costs roughly $2 billion per successful drug, and fails more than 90% of the time. If AI can meaningfully compress those timelines, reduce failure rates and lower costs, the implications for both patients and the pharmaceutical industry's economics would be profound.
The reality is more cautious. Isomorphic has not yet dosed a human patient. Its first clinical trials, originally targeted for the end of 2025, have been pushed back to the end of 2026. The company maintains partnerships with Eli Lilly, Novartis and Johnson & Johnson, deals collectively valued at several billion dollars, but these collaborations are structured around research milestones and contingent payments rather than approved products.
The $2.1 billion raise will fund three priorities: accelerating internal therapeutic programmes towards Phase 1 clinical trials, expanding the company's team across its London headquarters and offices in Cambridge, Massachusetts and Lausanne, and continuing to develop IsoDDE's capabilities across multiple therapeutic areas and drug modalities.
Ruth Porat, Alphabet's president and chief investment officer, said the company has "already made extraordinary progress in harnessing AI to accelerate drug discovery" and that the funding would bring "important interventions to market with greater speed."
Related reading
- Novo Nordisk deploys OpenAI tools companywide in bid to accelerate obesity and diabetes drug pipeline
- OpenAI Foundation to invest at least $1bn across health, safety and community programmes
- Binance's $10bn fraud prevention claim is impressive on paper, but the numbers deserve scrutiny
The competitive landscape has intensified since Isomorphic's $600 million Series A last year. Recursion Pharmaceuticals, Insilico Medicine, Xaira Therapeutics and a growing field of AI-native drug discovery companies are pursuing similar approaches, each claiming proprietary advantages in data, models or biology. Novo Nordisk's decision to sell its Parkinson's cell therapy to Cellular Intelligence, an AI biotech backed by Mark Zuckerberg, illustrates how quickly the sector is attracting capital and talent from outside traditional pharma.
For Isomorphic, the advantage is provenance. No other company in the space can trace its technology directly to a Nobel Prize-winning breakthrough, and no other company has a chief executive who simultaneously runs the world's most advanced AI research laboratory. Whether that scientific pedigree translates into approved drugs and commercial revenue remains the $10 billion question.The recap
- Isomorphic Labs raises $2.1 billion in external financing.
- Thrive Capital led the round; Alphabet also participated as investor.
- Company aims to develop artificial intelligence-designed drugs commercially.
